- Home
- TRNR vs ONCO Comparison
TRNR vs ONCO Comparison
Compare TRNR & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRNR | ONCO |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 2.3M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TRNR | ONCO |
|---|---|---|
| Price | $1.42 | $1.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 137.2K | ★ 1.9M |
| Earning Date | 05-18-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.80 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,530,000.00 | $815,371.00 |
| Revenue This Year | $245.67 | N/A |
| Revenue Next Year | $119.39 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 114.31 | N/A |
| 52 Week Low | $0.19 | $0.05 |
| 52 Week High | $8.20 | $7.65 |
Technical Indicators
Market Signals| Indicator | TRNR | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 54.56 | 53.90 |
| Support Level | $1.37 | $0.51 |
| Resistance Level | $1.62 | $2.01 |
| Average True Range (ATR) | 0.14 | 0.69 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 59.09 | 17.34 |
Price Performance
Historical ComparisonAbout TRNR Interactive Strength Inc.
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue and personal training revenue.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.